In a major move to resolve a decade of legal turmoil, Johnson & Johnson has announced a proposed $5.5 billion settlement to address approximately 76,000 lawsuits alleging that its talc-based products, including its iconic baby powder, are linked to ovarian cancer. While the company continues to maintain that its products are safe and free of asbestos, the deal represents an attempt to move past the protracted litigation that has shadowed its reputation. For the agreement to be finalized, it must secure approval from 95% of the affected claimants, potentially closing the door on nearly all remaining ovarian cancer cases currently pending in state and federal courts.

Despite the significant financial commitment, which is expected to be paid out between 2027 and 2028, company officials clarified that the settlement is a strategic move for closure rather than an admission of guilt. Legal experts representing the plaintiffs suggest the final payout could ultimately exceed $7 billion depending on participation rates, noting that the agreement offers a much faster resolution for victims than previous failed bankruptcy attempts. Although this settlement resolves existing claims, it does not provide legal immunity against potential future lawsuits, marking a distinct shift in strategy following J&J’s series of courtroom victories and the discontinuation of talc-based powder in the U.S. market.